HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hiding In Plain Sight: Can TTS Pharma’s ‘Assured Advice’ Unlock UK’s CBD Mass Market?

Executive Summary

UK CBD supplier TTS Pharma believes its strategy of establishing partnerhips with local food law enforcement agencies as part of the "assured advice" scheme will unlock the country's cautious mass market. However, without proactive enforcement, the company worries that the UK food authority's legislative efforts to remove sub-standard CBD products from the market, as well as TTS' own efforts to become compliant, will be in vain. 

You may also be interested in...



UK CBD Industry Embraces Trading Standards Partnership As Compliance Deadline Looms

UK CBD industry association, the ACI, joins others in forming partnerships with local authorities responsible for enforcing the new rules, which require all CBD food supplements on the market to hold a validated novel food application with the FSA. However, how effective enforcement will be in practice remains to be seen. 

Ascension Launches CBD Oil Under UK Flexiseq Osteoarthritis Brand

UK-based Ascension Healthcare has launched Flexiseq CBD under its flagship joint-pain relief brand. 

European Commission Decides CBD Is Not A Drug Opening Up Novel Food Pathway

The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.

Related Content

Topics

UsernamePublicRestriction

Register

RS150815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel